Generic and Off-Patent Pesticide Registration in Japan

Two things distinguish Japan from the jurisdictions most generic manufacturers know. There is no data-compensation system: a second applicant cannot cite the originator's studies and pay for the privilege. And there is a statutory equivalence route: since the 2018 amendment, an applicant whose active ingredient is equivalent in composition and toxicity to one already registered can be exempted from part of the data. The first fact makes Japan harder than it looks. The second makes it workable.

The legal basis

The amendment to the Agricultural Chemicals Regulation Act enacted on 15 June 2018 added, in Article 3(3), a provision allowing partial exemption from the required test data where the pesticide's active ingredient is equivalent to a registered active in composition and level of toxicity. The principal provisions took effect on 1 December 2018, with some review-procedure provisions following on 1 April 2020. From the same date, applications must include the types and content of non-active components in the technical material, the manufacturer, and the manufacturing process (MAFF, 2018 amendment). MAFF's stated purpose was to enable a better-quality and more affordable pesticide supply without lowering safety standards.

What equivalence requires

The requirement is operationalised in Table 1 of Notice 6278, Composition of the pesticide and the technical material. For the technical material it asks for the components and their content, the manufacturing method, the impurities expected from that method and their origin, a composition analysis including dioxins, the composition of the material used in the toxicity studies, upper and lower limits for each component, and, as its own item, the equivalence of the technical material.

In practice that means a specification and impurity profile of your technical material, usually from multi-batch analysis, compared against the reference material behind the existing registration. Where an impurity is new, or present above the reference level, the question becomes toxicological: whether it changes the hazard profile, and whether a bridging study is needed to show it does not. The composition of the material used in your toxicity studies has to match the material you will sell, which is why the sequence is specification first, studies second, formulation last.

What can be omitted, and what cannot

The exemption reaches the data that equivalence makes redundant, principally the parts of the human-health and environmental packages that characterise the active ingredient itself. It does not reach the studies that characterise your product in Japan. Efficacy and phytotoxicity trials on the Japanese crops and pests applied for, residue trials on those crops, and the formulation's own composition, stability, and analytical data remain yours to generate unless an omission condition in the notice applies. Notice 6278 also states, for its own reliance provisions, that an "already-registered pesticide" means one the applicant itself holds with rights to the data. The originator's dossier is not available to you by citation.

The result is a package that is targeted rather than full. For a generic manufacturer with an existing OECD-format dossier from another jurisdiction, the work is in three places: the equivalence case for the technical material, Japanese crop-specific trials, and the Japanese-language summaries the Food Safety Commission reads. The rest of the dossier, including the full study reports in English, generally carries across.

Timing and re-evaluation

Generic applicants file against actives that are, by definition, already registered, and every registered active in Japan now has a re-evaluation deadline. Where your filing lands relative to that active's published data-submission deadline decides whether it is reviewed normally, in parallel with the re-evaluation, or deferred until the re-evaluation concludes. For an off-patent active that is high-volume in Japan, the deadline may already be close. Check it before committing to a programme; our re-evaluation guide explains the four tracks.

Who this route is for

Generic manufacturers in India and China, European mid-sized crop-protection groups extending mature portfolios, US companies with established chemistry, and companies acquiring off-patent molecules whose rights include or could include Japan. The common feature is an existing dossier and a technical material whose specification can be documented. The common mistake is assuming either that Japan needs a full new package or that it accepts a citation to the originator's data; both cost time. We build and file the equivalence case and manage the registration on the reduced package. See Japan pesticide registration support.